CONDITIONAL OK GIVEN FOR CEPHALON'S SPARLON

Cephalon has received conditional FDA approval from regulators for Sparlon, a treatment for attention-deficit/hyperactivity disorder (ADHD) that has the same active ingredient as the company's Provigil.

Sparlon, which had been previously known as Attenace, is designed for ADHD in children and adolescents aged 6 through 17. Cephalon expects to launch Sparlon in early 2006, depending upon final FDA approval.